0 Table of Contents |
1 Home |
2 IDMP Standard ISO 11615 |
3 Datasource Authorised Medicinal Product |
4 Dataexport FOPH Spezialitätenliste |
5 Use Cases |
6 Cuprior |
7 Entocort |
8 Estalis |
9 Keytruda |
10 Paxlovid |
11 Triogen |
12 Profiles |
13 Extensions |
14 Terminology |
15 Artifacts Summary |
15.1 CH EPL Organization |
15.2 CH IDMP AdministrableProductDefinition |
15.3 CH IDMP ClinicalUseDefinition Indication |
15.4 CH IDMP DocumentReference |
15.5 CH IDMP ManufacturedItemDefinition |
15.6 IDMP Bundle |
15.7 IDMP Ingredient |
15.8 IDMP MedicinalProductDefinition |
15.9 IDMP PackagedProductDefinition |
15.10 IDMP RegulatedAuthorization |
15.11 FOPH Dossier Number |
15.12 GLN Identifier |
15.13 LOC Identifier |
15.14 CH - EPL Full Limitation Text |
15.15 CH - EPL Product Price |
15.16 CH - EPL Regulated Authorization Limitation |
15.17 CH - EPL Reimbursement SL |
15.18 CH - SMC Authorized Dose Form |
15.19 CH - Authorisation Type |
15.20 CH - Medicinal Product Name Type |
15.21 CH - Other Characteristics Type |
15.22 CH EPL - Gamme |
15.23 CH EPL - Limitation Status |
15.24 CH EPL - Listing Status |
15.25 CH EPL - Other Characteristics Packaged Item |
15.26 CH EPL - Price Type |
15.27 CH EPL - Product Type |
15.28 CH EPL - Reimbursement Status |
15.29 CH EPL - Type of Price Change |
15.30 CH SMC - Attached Document Type |
15.31 CH SMC - Authorisation Category |
15.32 CH SMC - Authorisation Status |
15.33 CH SMC - Authorised Pharmaceutical Dose Form |
15.34 CH SMC - Ingredient Role |
15.35 CH SMC - Legal Status of Supply |
15.36 CH SMC - Marketing Status |
15.37 CH SMC - Pediatric Use Indicator |
15.38 CH SMC - Special Precautions for Storage |
15.39 CH SMC - Substance |
15.40 CH SMC - TherapeuticProductcode |
15.41 CH SMC- Additional Monitoring Indicator |
15.42 EDQM - Combination Packaging |
15.43 EDQM - Combined Pharmaceutical Dose Form |
15.44 EDQM - Combined Term |
15.45 EDQM - Packaging |
15.46 EDQM - Pharmaceutical Dose Form |
15.47 EDQM - Route Of Administration |
15.48 EDQM - Unit of Presentation |
15.49 EMA - Domain |
15.50 EMA - Intended Effect |
15.51 EMA - Shelf Life Type |
15.52 CH - Authorisation Type |
15.53 CH - Medicinal Product Name Type |
15.54 CH - Other Characteristics Type |
15.55 CH EPL - Gamme |
15.56 CH EPL - Limitation Status |
15.57 CH EPL - Listing Status |
15.58 CH EPL - Other Characteristics Packaged Item |
15.59 CH EPL - Price Type |
15.60 CH EPL - Product Type |
15.61 CH EPL - Reimbursement Status |
15.62 CH EPL - Type of Price Change |
15.63 CH SMC - Additional Monitoring Indicator |
15.64 CH SMC - Attached Document Type |
15.65 CH SMC - Authorisation Category |
15.66 CH SMC - Authorisation Status |
15.67 CH SMC - Ingredient Role |
15.68 CH SMC - Legal Status of Supply |
15.69 CH SMC - Marketing Status |
15.70 CH SMC - Pediatric Use Indicator |
15.71 CH SMC - Special Precautions for Storage |
15.72 CH SMC - Substance |
15.73 CH SMC - TherapeuticProductcode |
15.74 EDQM - Standard Terms |
15.75 EMA - Domain |
15.76 EMA - Intended Effect |
15.77 EMA - Shelf Life Type |
15.78 5204201 |
15.79 52042011 |
15.80 5470402 |
15.81 54704089 |
15.82 66231001 |
15.83 6623101 |
15.84 67431001 |
15.85 6743101 |
15.86 67719001 |
15.87 6771901 |
15.88 68793001 |
15.89 6879301 |
15.90 CH-52042011 |
15.91 CH-54704089 |
15.92 CH-66231001 |
15.93 CH-67431001 |
15.94 CH-68291001 |
15.95 CH-68793001 |
15.96 CUPRIOR Filmtabl 150 mg 72 Stk |
15.97 CUPRIOR Filmtabl 150 mg 72 Stk (Bundle) |
15.98 Cuprior, Filmtabletten Fachinformation |
15.99 Cuprior, Filmtabletten Patienteninformation |
15.100 ENTOCORT Enema Klistier Lösung + Tabletten 7 Stk |
15.101 ENTOCORT Enema Klistier Lösung + Tabletten 7 Stk (Bundle) |
15.102 ENTOCORT Enema Klistier Lösung + Tabletten 7 Stk Fachinformation |
15.103 ENTOCORT Enema Klistier Lösung + Tabletten 7 Stk Patienteninformation |
15.104 ESTALIS Matrixpfl 50/250 24 Stk |
15.105 ESTALIS Matrixpfl 50/250 24 Stk (Bundle) |
15.106 ESTALIS Matrixpfl 50/250 24 Stk Fachinformation |
15.107 ESTALIS Matrixpfl 50/250 24 Stk Patienteninformation |
15.108 Indication 10009900 |
15.109 Indication 10019927 |
15.110 Indication 10021782 |
15.111 Indication 10027400 |
15.112 Indication 10028881 |
15.113 Indication 10030247 |
15.114 Indication 10031285 |
15.115 Indication 10043971 |
15.116 Indication 10061091 |
15.117 Indication 10075566 |
15.118 Indication 10084529 |
15.119 KEYTRUDA Inf Konz 100 mg / 4 ml |
15.120 KEYTRUDA Inf Konz 100 mg / 4 ml (Bundle) |
15.121 Keytruda, Konzentrat zur Herstellung einer Infusionslösung Fachinformation |
15.122 Limitation 254837009 |
15.123 Limitation 79886009 |
15.124 Limitation 840539006 |
15.125 MI Budesonidum-2.3mg-Tablet |
15.126 MI Estradiol-hemihydrate-Norethisteroni-acetas-Transdermal-patch |
15.127 MI Nirmatrelvir-150mg-Tablet |
15.128 MI Pembrolizumab-100mg-Vial |
15.129 MI Ritonavirum-100mg-Tablet |
15.130 MI Solvent |
15.131 MI Trientinum-150mg-Tablet |
15.132 MI Trientinum-250mg-Capsule |
15.133 PAXLOVID Filmtabl 4x150mg/2x100mg |
15.134 PAXLOVID Filmtabl 4x150mg/2x100mg (Bundle) |
15.135 Paxlovid, Filmtabletten Patienteninformation |
15.136 PhP Budesonidum-Suspension |
15.137 PhP Estradiol-hemihydrate and Norethisteroni-acetas Transdermal-patch |
15.138 PhP Pembrolizumab-100mg-Vial |
15.139 PhP Trientinum-150mg-Tablet |
15.140 PhP Trientinum-150mg-Tablet |
15.141 PhP-Nirmatrelvir-150mg-Filmcoatedtablet |
15.142 PhP-Ritonavirum-100mg-Filmcoatedtablet |
15.143 Professional Information Paxlovid, Filmtabletten Fachinformation |
15.144 Reimbursement SL 17418 |
15.145 Reimbursement SL 17973 |
15.146 Reimbursement SL 20416 |
15.147 Reimbursement SL 21070 |
15.148 Reimbursement SL 21208 |
15.149 Reimbursement SL 21529 |
15.150 TRIOGEN Kaps 250 mg Ds 100 Stk |
15.151 TRIOGEN Kaps 250 mg Ds 100 Stk (Bundle) |
15.152 Triogen, Kapseln Fachinformation |
15.153 Triogen, Kapseln Patienteninformation |